Harlan Project B52020

Beryllium

Expert Study Evaluation of the Epidemiological and Toxicological Scientific Literature on Carcinogenicity of Beryllium Metal & Beryllium-containing Alloys

Expert Statement

October 28, 2010

Author: Christian Strupp, Dr. rer. nat.
        Bjarte Furnes, PhD
        Harlan Laboratories Ltd.
        Zelgliweg 1
        CH-4452 Itingen
        Switzerland


CONTENTS

1 Purpose.......................................................................................................................... 2
2 Classification History..................................................................................................... 3
3 Human Health Effects..................................................................................................... 5
  3.1 Acute Beryllium Disease ............................................................................................. 5
  3.2 Beryllium sensitization ............................................................................................... 6
  3.3 Chronic beryllium disease .......................................................................................... 6
  3.4 Lung cancer ................................................................................................................ 7
    3.4.1 Literature Review Protocol ................................................................................. 8
    3.4.2 Summary of Literature Review: Animal and in vitro Studies ......................... 9
    3.4.3 Summary of Literature Review: Epidemiological Studies and Data .............. 15
    3.4.4 Summary of new studies performed on Beryllium metal .............................. 18
4 Summary and Conclusions ............................................................................................. 21
Appendix 1 ........................................................................................................................ 24
Appendix 2 ........................................................................................................................ 26
Appendix 3 ........................................................................................................................ 42
Appendix 4 ........................................................................................................................ 45
Appendix 5 ........................................................................................................................ 52

1 PURPOSE

The REACH Beryllium Consortium commissioned Harlan Laboratories Ltd., Switzerland, to prepare an analysis of the scientific literature on beryllium metal and beryllium-containing alloys relative to carcinogenicity. Studies dealing with animal testing were evaluated by toxicologists from Harlan Laboratories Ltd, and epidemiological aspects of the scientific literature were analysed by epidemiology experts of the REACH Beryllium Consortium. Additional testing of beryllium metal was also performed by Harlan Laboratories Ltd. These tests were performed according to OECD guidelines and under GLP. The outcome of the evaluation of existing scientific literature and new studies has been compiled into the present document.

This analysis is a fact-based analysis of the classification history. In addition, the scientific literature was screened for study data relevant for carcinogenicity and the data evaluated for its quality and its significance/adequacy regarding human health effects.
2 CLASSIFICATION HISTORY

Insoluble forms of beryllium include beryllium metal, beryllium aluminum composites (AlBeMet), beryllium oxide (BeO) and alloys containing beryllium such as copper beryllium (CuBe). These insoluble forms comprise nearly the entire commercial market for beryllium. As with many metals, the toxicity profile of soluble beryllium compounds differs from that of pure beryllium metal and differs also from that of beryllium-containing alloys due to the physicochemical differences.

However, in the European Community and later European Union, beryllium metal and beryllium compounds were classified and labelled as being toxicologically identical. An extensive search was undertaken to locate the documentation as to the basis used and the studies employed for determining the classification of beryllium metal and beryllium compounds. Except for the sparse information on the environmental aspects that was documented during the latest step in classification (2001), no other supporting documentation was found.

Classification and labeling (C&L) of beryllium was introduced in the European Community in 1967 (EC 1967). Beryllium and beryllium compounds were classified for the first time in the Council Directive 67/548/EEC. Changes of the classification and labeling of beryllium and beryllium compounds were made by the 19. ATP Commission Directive 93/72/EEC in Sept. 1993. Changes of the classification comprised Carcinogenicity Category 2; R49, “May cause cancer by inhalation” which is the current classification. Both of these classifications appear to accept the earlier classification since no separate documentation could be located that would indicate that a new evaluation was performed. Beryllium is also classified according to the Globally Harmonised System of Classification and Labelling of Chemicals (Regulation 1272/2008). The current GHS classification with regards to carcinogenicity is H350i (Category 1B: presumed to have carcinogenic potential for humans, classification is largely based on animal evidence) which is a translation of the R49 classification (Annex VII of Regulation 1272/2008).

Because no documented rationale could be found, several sources were evaluated in an attempt to determine the rational for the existing classification. The European Chemicals Bureau (ECB) and the German Federal Institute for Occupational Safety and Health (BAuA) were contacted by Harlan Laboratories Ltd. to determine whether such a rationale exists and if it is available. BAuA responded that their documentation is limited to protocols of sessions and that they do not have a documented rationale for the changes of the classification as carcinogenic (if any exist). Furthermore, the information was given that due to disagreement among the Member States with respect to the classification as carcinogenic the Specialized Experts (a Scientific Committee of the EU Commission) were charged to deal with this issue. The Committee unanimously voted for the category C2. This advice was finally adopted by the Member States. The response of ECB was similar to that of BAuA. The only documentation they have were summary records of the meetings of the C&L Working Group and the discussions between the delegations of the Member States.

The documentation delivered by ECB is also not complete since the final classification of beryllium metal and beryllium compounds deviates from the “provisional” classification.
which was agreed and which was noted in the summary record from 13.8.1990 with respect to some of the risk phrases: The provisional classification of beryllium and beryllium compounds does not include the risk phrases R 25, R 26, R 36/37/38, R43 which are contained in the final C&L. It should be noted here that the phrases R25, R43, and R36/37/38 are appropriate for soluble beryllium compounds, but have not been investigated by appropriate animal studies and from the physico-chemical properties are unlikely to be appropriate for beryllium metal or beryllium-containing alloys. Appropriate animal studies were therefore performed and are summarized in 3.4.4 of this document. These studies do not support these classifications.

In summary, there is no documentation that clearly articulates the basis for the current classification of beryllium metal, beryllium-containing alloys and compounds or any of the studies utilized to support the cancer classification within the EU. Even though the toxicity of beryllium metal and beryllium-containing alloys differs from beryllium compounds, the international agencies and national institutions appear to not recognize these differences.
3  HUMAN HEALTH EFFECTS

The following section provides a basic overview of the health effects associated with beryllium and beryllium compounds. The different forms of “beryllium” are often not specified in the literature. The differentiation of beryllium metal, beryllium-containing alloys and beryllium compounds is important because of different physicochemical properties of the different forms, resulting in different toxicity profiles. Accordingly, these compounds should be evaluated separately and classified as such. Toxicologically relevant exposure to beryllium is almost exclusively confined to the work-place. The following health effects have predominantly been reported in workers exposed to beryllium:

- Acute beryllium disease - a form of severe respiratory disease associated primarily with exposure to soluble compounds;
- Dermatitis and skin sensitization have been associated with soluble beryllium compounds;
- Chronic beryllium disease – forms can include subclinical CBD (asymptomatic) and clinical CBD (symptomatic);
- Lung cancer

Dermatitis and skin sensitization have also been associated with exposure to soluble beryllium compounds.

3.1  Acute Beryllium Disease

Acute Beryllium Disease (ABD) is an acute toxic chemical pneumonitis resulting from high exposure to soluble beryllium compounds (beryllium salts such as beryllium fluoride and beryllium chloride) or low-fired beryllium oxide. Due to the current high standard of worker protection measures during processing of beryllium, ABD has very rarely been diagnosed during the last decades and low-fired beryllium oxide has not been commercially available since 1950 (Eisenbud et al, 1955).

The onset of symptoms of ABD was usually immediate, but could be delayed from several hours up to 3 days. Symptoms included dyspnea, fatigue, fever, night sweats and cough. Pulmonary function tests revealed obstructive lung disease with impaired gas exchange. Most of the cases of ABD usually resolved completely. However, some were fatal or were followed by development of chronic beryllium disease (Ordstrand et al, 1945). Cases of ABD have only been shown to occur when airborne concentrations of soluble beryllium salts or low fired beryllium oxide exceed 100 µg Be/m$^3$ (Eisenbud, 1982). Airborne exposures to beryllium metal, high-fired beryllium oxide or beryllium-containing alloy fumes or dust are not associated with acute or short-term respiratory reactions (Ridenour et al., 1991; Eisenbud, 1982, 1984$^1$).

$^1$ Although Eisenbud named a potential of metallic beryllium to induce ABD in his first publication (1955), this hypothesis was not repeated in later publications. In the latest publication (1984), he claimed that diagnosis of ABD after beryllium metal exposure was questionable.
3.2 Beryllium sensitization

Beryllium sensitisation (BeS) is an immunologically mediated reaction to repeated Beryllium exposure (allergic reaction). Although the sensitisation itself is not a disease and is symptomless, it is a critical factor for development of CBD. Beryllium has been demonstrated to bind to proteins and form antigens (Vacher, 1972), thereby triggering the immune response responsible for the allergic reactions. A relatively weak beryllium-sensitisation was detected in humans by the beryllium skin patch test (BePT, Curtis 1951) for powdered beryllium metal (3 of 13 workers), however no sensitization was observed with a beryllium metal disk. This study demonstrated a clear difference to the soluble Be compounds as these elicited a much stronger reaction in almost all workers tested. The use of the BePT was curtailed because simultaneous experimental application of multiple tests sensitized members (positive patch test) of control populations and because it was suggested that the test itself might trigger BeS (Epstein, 1991) or exacerbate existing cCBD (Waksman, 1959).

3.3 Chronic beryllium disease

Chronic beryllium disease (CBD) is a systemic granulomatous disorder that requires a beryllium-specific immune response (Deubner DC et al., 2007). A latency period of several weeks to more than 20 years is characteristic for CBD. Granuloma formation can exist with no symptomology or physical impairment of health, this form of CBD being called subclinical CBD (sCBD). If symptoms are present, the form of CBD is termed clinical CBD (cCBD). The clinical course of cCBD is considered highly variable since the symptomatic disease may not develop or it may develop slowly over time. The earliest manifestations of clinical chronic beryllium disease (cCBD) are the symptoms of shortness of breath, dry cough, or wheeze, and in some, night sweats or fatigue. Chest radiographs can be normal, but often range from small nodular opacities, with an upper level predominance, to formation of conglomerate masses (Mueller-Quernheim, et al., 2005). Progression may lead to weight loss, cor-pulmonale with heart failure, disability and death. In addition to cCBD, these symptoms may be found in persons with other lung diseases and in persons with no diagnosable disease (Murray JF et al.).

Chronic Beryllium Disease was diagnosed, before the late 1980s, when clinical symptoms were observed along with changes in chest X-rays or lung function tests. In the late 1980s a change in the criterion for diagnosis of CBD was first suggested (Kreiss, H, et al., 1989), applying abnormal lymphocyte proliferation tests for beryllium sensitisation in blood or lung fluid (BeLPT, Beryllium lymphocyte proliferation test) and the presence of non-caseating granulomas in lung biopsy. The BeLPT has never been validated correctly, and there is evidence of bad performance (Cher 2006, Borak 2006, Donovan 2007), leaving doubts on the reliability of the test.

It is due to the change of diagnostic methods that before the late 1980s all reported cases of CBD were symptomatic, while afterwards due to improved diagnostics a big part of the described cases were asymptomatic. This is important when reviewing epidemiological data. The BeLPT needs careful validation. A positive BeLPT leads to severe psychosocial and socio-economic consequences, because workers are often advised to cease beryllium-exposure, with the consequence of giving up their jobs and subsequent loss of income.
Not all persons exposed to beryllium develop BeS, and even fewer develop CBD. Additional factors specific to individual persons (genetic polymorphisms, underlying infections, lifestyle factors?) seem to play a crucial role.

3.4 Lung cancer

Since about 1950, a series of in vivo animal studies on the carcinogenicity of beryllium and its compounds have been conducted. Most of these studies investigated the inhalation route because this route appears to be most relevant for humans in workplaces. Only in rats and sensitive mouse strains a clear carcinogenic response to beryllium metal-exposure could be demonstrated, while no or equivocal response was observed in wild-type mice.

According to published epidemiologic reports, there is no evidence or studies to suggest the beryllium containing alloys are carcinogenic to humans. A number of epidemiology studies using the same population have been conducted to assess the carcinogenic potential of beryllium compounds and its soluble salts. These studies were analyses and re-analyses of cohorts at the same beryllium producing plants in the United States. Increased incidences of lung cancer deaths were reported in retrospective cohort mortality studies of these workers. No clear correlation between the incidence of lung cancer deaths and levels or duration of exposure has been established because historical exposure levels were not reported. A positive association between length of latency and lung cancer deaths was reported with the highest cancer risks associated with a latency of more than 25 years. This was later proven to be inaccurate by Deubner and Levy. The evidence for excess lung cancer in beryllium workers is weak, both because it is derived primarily from short tenure workers, known to have relatively high SMRs for lung cancer. Also, because of the findings that the excess is fragile and disappears with reasonable variations of the study approach, evaluating the available literature on the potential carcinogenicity of exposure to beryllium along with the history behind some of that literature is important to a complete understanding as to whether findings, statements and conclusions provided in the cancer references are relevant when there is new knowledge that either supports, supersedes or invalidates earlier findings or interpretations. The studies by Levy (2002, 2007, 2009), Brown (2004) and a new study by Deubner (2007) provide new evidence that exposure to beryllium does not convey a significant risk of cancer to humans. In addition, both Levy 2007 and Deubner 2007 identified a significant methodological error in the Sanderson study which they suggest negates the use of this study as a dose/response cancer link for beryllium. The latest study, Schubauer-Berigan 2010, did not find a significant increase in risk of cancer following working with beryllium.

A manuscript prepared by the European Commission on beryllium in relation to occupational diseases (Information Notices on Occupational Diseases: A Guide to Diagnosis, 2009) states that “the causal relationship between prolonged or repeated exposure to beryllium and the occurrence of bronchial cancer has not been firmly established, and due to the multicausality of the occurrence of this type of cancer, the recognition of the occupational origin must lie on a thorough assessment based on rigorous scientific criteria taking into account all possible aetiologies. Each case must therefore be considered separately”.

7
The newer studies are rigorous and they deal with sizeable cohorts exposed to very high levels of beryllium. Failure to find convincing evidence that beryllium workers have excess rates, combined with clear evidence that in beryllium workers lung cancer is not related to degree of exposure, supports a reclassification of beryllium as non-carcinogenic in humans.

3.4.1 Literature Review Protocol

The scientific literature was screened for publications addressing potential genotoxicity and carcinogenicity of beryllium.

The reliability of the data is a key initial consideration in a weight-of-evidence analysis and provide an indication of which studies should be evaluated more closely. Without knowledge of how a study was conducted all other considerations and potential conclusions drawn from this study may be irrelevant. An approach used to assist the initial screening of study reports is that developed by Klimisch et al. (1997). Those studies receiving a Klimisch rating of 1 or 2 are considered adequate to support data assessment needs. This approach was developed as a scoring system for reliability as follows:

1 = reliable without restrictions: “studies or data generated according to generally valid and/or internationally accepted testing guidelines (preferably performed under Good Laboratory Practices (GLP)) or in which the test parameters are based on a specific (national) testing guideline, or in which all parameters described are closely related/comparable to a guideline method.”

2 = reliable with restrictions: “studies or data (mostly not performed according to GLP), in which the test parameters documented do not totally comply with the specific testing guideline, but are sufficient to accept the data or in which investigations are described which cannot be subsumed under a testing guideline, but which are nevertheless well documented and scientifically acceptable.”

3 = not reliable: “studies or data in which there were interferences between the measuring system and the test substance or in which organisms/test systems were used which are not relevant in relation to the exposure (e.g., unphysiologic pathways of application) or which were carried out or generated according to a method which is not acceptable, the documentation of which is not sufficient for assessment and which is not convincing for an expert judgment.”

4 = not assignable: “studies or data which do not give sufficient experimental details and which are only listed in short abstracts or secondary literature (books, reviews, etc.).”

Nevertheless, in case no high-quality studies to address endpoints required for risk assessment were present, all available material was evaluated. A search strategy of relevant data bases (Appendix 1) was developed for the literature search and the results for “beryllium” produced 1531 hits after non-relevant articles were discarded. The literature hits were manually screened by toxicology experts for relevance in regard to genotoxicity and carcinogenicity of beryllium metal, alloys and compounds. If the information provided in title and abstract was not sufficient to judge the relevance of the study, full articles were ordered and evaluated. By expert judgment, 38 publications containing experimental study data for carcinogenesis and 21 publications containing
experimental study data for genotoxicity of beryllium and/or its compounds were identified.

Additional new studies on beryllium metal were performed by Harlan Laboratories Ltd. These studies were all performed according to OECD guidelines and under GLP conditions. These studies are therefore summarized separately in Section 3.4.4.

3.4.2 Summary of Literature Review: Animal and in vitro Studies

The complete listing of the studies assessed, including a short description of the evaluated parameters and their Klimisch rating, are presented in Appendix 2.

It must be stated that most, if not all of the animal and in vitro studies, do not comply with modern requirements of study conditions, e.g. described in OECD Guidelines. None of these studies were conducted according to GLP, in particular many of the older studies do not have an appropriate control group or the study conditions and/or results are not adequately reported. Thus, the reliability of many studies was rated according to Klimisch et al. (1997) as not reliable (Rating 3) or not assignable (Rating 4). The great majority (84%) of the studies were performed using soluble beryllium compounds with a few performed using beryllium metal or alloys.

Some studies have been heavily criticized by associated staff, claiming that conduct and reporting of studies was inadequate. Study results were partly published by authors other than the experimentator without correspondence about potential weaknesses of the data; partly only by oral communication/in abstract or tabular form without any description of the used methods, and technicians conducting the studies were not adequately trained (Reeves, 1987). Furthermore, results of an inhalative monkey study conducted by Vorwald (Vorwald, 1968) have been reported in a misleading way. The intention was not to prove carcinogenicity of beryllium, but to demonstrate that the monkey in general was a model for carcinogenicity. Animals were not only exposed to beryllium, but to cigarette smoke and other “exposures that were expected to be co-carcinogenic” as well. Thus, the study cannot be taken into account for risk assessment (protocol of the public hearing on 31st of August, 1977 at the US OSHA).

The intention of this document is to clearly distinguish the discussion of beryllium metal and alloys from the discussion of soluble beryllium compounds. Due to the different physico-chemical behavior of the different forms of beryllium (e.g. solubility under physiologic conditions, with great impact on bioavailability), this separation seems appropriate. Furthermore, this document should give a statement on the quality of the study data being the basis of classification of beryllium.

In vitro studies

The predictiveness of in vitro studies has been shown and validated for genotoxicity. Among the 21 identified studies, there were no reliable in vitro studies on beryllium metal or beryllium-containing alloys. A complete listing of these studies can be found in Appendix 2. Most of the studies were conducted with soluble compounds, while testing of extracts from the metal would be appropriate to test these insoluble compounds.
Additional *in vitro* studies on Be metal were therefore performed by Harlan Laboratories Ltd. These studies are summarized separately in Section 3.4.4. As a pre-test, a study on cytotoxicity of beryllium metal powder extract (10% test item in saline for 24 hours) has been performed in L929-cells. No signs of cytotoxicity were observed when the pure extract was applied to the cells, indicating either no relevant ion formation (= no bioavailability) or non-toxicity.

**In vivo Animal Studies**

Since about 1950, a series of studies on the carcinogenicity of beryllium and its compounds have been conducted. Most of these studies investigated the inhalation route because this route appears to be the most relevant for humans in workplaces.

**Soluble beryllium compounds**

A large number of studies addressing carcinogenicity have been performed with soluble beryllium compounds. The complete listing of the studies assessed and their Klimisch rating are presented in Appendix 2.

**Beryllium metal**

There are only twelve (12) animal studies available addressing carcinogenicity of inhaled beryllium metal or alloy (see table below)\(^2\). These studies are summarized in Appendix 3. Five studies suggest carcinogenicity of inhaled beryllium metal in the rat, three studies suggest carcinogenicity in sensitive mice (A/J or p53-knockout), four studies suggest non-carcinogenicity in wild-type mice and one study suggests non-carcinogenicity in guinea pigs.

**Table 1 Summary of *in vivo* studies assessing the carcinogenicity of beryllium metal**

<table>
<thead>
<tr>
<th>Test Animal, Route of Exposure</th>
<th>Carcinogenic response identified</th>
<th>Data Quality [Klimisch 1-4]</th>
<th>Reference</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Rat inhalation</strong></td>
<td>rats: yes</td>
<td>2</td>
<td>Finch et al., 1994, 1995 and, 1996; Belinsky et al., 1994; Nickel-Brady et al., 1994; Nikula et al., 1995; Belinsky et al., 1997</td>
</tr>
<tr>
<td><strong>Rat intratracheal instillation</strong></td>
<td>yes</td>
<td>4</td>
<td>Groth et al., 1980</td>
</tr>
</tbody>
</table>

\(^2\) One additional study by Hueper et al. (1954) addressed carcinogenicity of beryllium metal, but the route of delivery (intrapleural and intrafemural bolus application) is not considered physiologically relevant.
<table>
<thead>
<tr>
<th>Animal</th>
<th>Method</th>
<th>Details</th>
<th>Reference</th>
</tr>
</thead>
<tbody>
<tr>
<td>Rat</td>
<td>Intratracheal instillation</td>
<td>Yes, 4 (too little experimental details given to evaluate the study)</td>
<td>Litvinov et al., 1983</td>
</tr>
<tr>
<td>Mouse</td>
<td>Inhalation</td>
<td>Sensitive mouse strains: weakly, wild-type mice: no 2 (well-documented, guideline-comparable study)</td>
<td>Finch et al., 1995, 1996 and 1998b</td>
</tr>
<tr>
<td>Guinea pig</td>
<td>Intratracheal instillation</td>
<td>No, 4 (no details on experiment)</td>
<td>Schepers et al., 1961</td>
</tr>
</tbody>
</table>

The studies by Groth and Schepers are not inhalation studies. Beryllium metal and alloy were administered by intratracheal administration. By this method, a small sample of the test substance is once or repeatedly instilled as a suspension or solution into the lung. This route has two disadvantages: the upper respiratory tract is not exposed, and the bolus application results in unavoidably high local concentrations of beryllium metal or alloy in the lower lobes of the lung (Vorwald, 1959). Accordingly, studies of this type are not considered being suitable for classification or risk assessment issues.

Other studies with beryllium metal and alloys address acute and chronic toxicity as well as histopathological changes in mice and monkeys, but do not allow direct conclusions on carcinogenicity (Curtis 1951, Ferraris 1952, Haley et al., 1990/92/94; Finch et al., 1991/93/94/98; Zissu et al., 1996; Nikula et al., 1997; Benson et al., 2000).

An association between beryllium metal exposure and lung tumors was only observed in rats and sensitive mouse-strains, but could not be demonstrated in wild-type mice (Nikula, 1995; Finch et al., 1995; Finch et al. 1996) and guinea pigs (Schepers, 1961)\(^3\). This observation was also documented by Finch and Hoover (History of the LRRI Beryllium Research Program, August 1999) in a document “Overview and Publications of the Lovelace Respiratory Research Institute Beryllium Respiratory Research Program.” The investigator staff at the Lovelace Institute was comprised of Belinsky, Benson, Finch, Hoover, and Nikula whose studies were evaluated in this analysis. The authors stated:

“Published reports by other workers on the issue of beryllium carcinogenicity are contradictory, plagued with experimental design problems and inconclusive for predicting carcinogenicity of beryllium in humans. An additional factor has been the controversy surrounding the cancer epidemiology studies in beryllium workers. Our results demonstrated that inhaled beryllium metal is a potent lung carcinogen in rats. We subsequently extended these studies to mice to further our understanding of beryllium-induced carcinogenic process, and relevance to humans. Results indicate beryllium metal at similar lung burdens is not a pulmonary carcinogen to C3H mice and is weak in A/J mice.”

The disconnect between carcinogenicity in the rat (the robust response at relatively low lung burdens) versus the missing response in wild-type mice maybe explained with the long-term chronic-active inflammation in rat lung, as stated by Dr. Gregory Finch (who

\(^3\) It should be noted that study period was limited to 3 months
was part of the team investigating inhalation toxicity of beryllium in the biggest test battery ever performed on this issue)

"[...] an obvious fundamental question is how relevant are animals to humans. For beryllium, given the body of evidence that Be is not genotoxic, the mechanism of carcinogenesis is not clearly known. Thus, [...] the presumption would be that the mechanism is also relevant to humans. However, where Be has always "hung up" for me is [...] the disconnect between carcinogenicity in the rat [the robust response at relatively low lung burdens] versus the weak- to non-existing response in mice [AJ, C3H, and the p53 +/- TGs we did]. For the rat, we always had the view that the long-term chronic-active inflammation in rat lung [with relatively strong neutrophilic "foreign body-type" response] was sufficient to lead to neoplasms, whereas for the mouse, the inflammation had more of a lymphocytic ["immune"] versus neutrophilic response, and they didn't have much of a carci signal." 4

On the basis of these experimental results, the species-specific specialities of the rat should receive a closer look before risk extrapolation to humans is made. An age-dependent increase of chronic active inflammation in rats has been noted by the US National Toxicology Program (NTP, 1996). A review of 24 chronic inhalation studies conducted by NTP over 10 years revealed that mean incidence of chronic active inflammation in unexposed control mice was low (1.4%), the incidence was about factor 7 higher in rats (10.2%) (Sivulka, 2006).

If there is a predisposition of rats to develop inflammation while they age, this may have severe impact on carcinogenesis if particulate matter –like insoluble metal-compounds- is present in the lung. This can be supported by an analysis of inhalation studies conducted at NTP (reported effects were limited to those considered of greatest biological significance (i.e., any form of inflammation, fibrosis, proteinosis):

<table>
<thead>
<tr>
<th>Compound</th>
<th>Effect</th>
<th>LOAEC [mg compound/m³]</th>
<th>Incidence (%)</th>
<th>Severity8</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td>Mice</td>
<td>Rats</td>
<td>Mice</td>
</tr>
<tr>
<td>MoO₃</td>
<td>Chronic Inflammation</td>
<td>&gt;100⁹</td>
<td>30</td>
<td>N/A</td>
</tr>
<tr>
<td>CoSO₄</td>
<td>Granulomatous inflammation, fibrosis, and proteinosis</td>
<td>&gt; 3⁷</td>
<td>0.3</td>
<td>N/A</td>
</tr>
<tr>
<td>NiSO₄</td>
<td>Chronic active inflammation (rats and mice), fibrosis (rats only), and</td>
<td>0.25</td>
<td>0.25</td>
<td>12⁷</td>
</tr>
</tbody>
</table>

4 Note to Marc Kolanz, 12th of Dec 2002
5 Average severity grade of lesions in affected animals: 1=minimal, 2=mild, 3=moderate, 4=marked
6 Mice showed no evidence of inflammation at any doses tested. The highest dose tested was 100 mg MoO₃/m³. Any LOAEC would presumably have been higher than this dose.
7 Mice showed no evidence of inflammation, fibrosis, or proteinosis at any doses tested. The highest dose tested was 3 mg CoSO₄/m³. Any LOAEC for these effects would presumably have been higher than this dose.
8 Chronic active inflammation seen in female mice, only.
Rats appear to be considerably more sensitive to the non-neoplastic respiratory effects of these compounds than mice. The solubility of the metal compound seemed to make no difference in the effects seen in rats versus mice. Respiratory toxicity effects tended to manifest themselves at lower doses, at higher incidences, and greater severity in rats than in mice.

The reason for the difference between rat and mouse/guinea pig can only be speculated. However, there is increased evidence that rats are particularly sensitive to inhalation effects of poorly soluble particles due to reduced lung clearance rates relative to other species. This is related to both the airway geometry of the rat lung and the reduced macrophage capacity. The impaired alveolar macrophage function leads to accumulation of particles and focal accumulation of particle-laden alveolar macrophages. In rats, these events may lead to inflammation and cell proliferation, with the final consequence of lung tumors. There is an ongoing scientific debate regarding how to interpret data, and the relevance to human exposure, from rat inhalation studies of poorly soluble particles (e.g. ILSI Risk Science Institute Workshop, 2000). There is scientific support that neoplastic effects seen in rat studies of non-genotoxic poorly soluble substances under overload conditions may not be relevant for the human risk assessment.

An overall evaluation of the carcinogenicity studies with beryllium-compounds (including studies with soluble beryllium compounds) suggests that the induction of pulmonary cancer by beryllium metal and beryllium compounds maybe species-specific. A listing of the inhalation studies available is given in Appendix 3.

While rats were susceptible, no pulmonary tumours were observed in wild-type mice (Finch et al., 1996), guinea-pigs (Reeves, 1987) and hamsters (Wagner 1969). Only one case of a pulmonary tumor was described in rabbit (Dutra et al., 1951) upon inhalation of beryllium oxide. A number of studies with intravenous, intraossal, intrathoracical or intraocular administration of beryllium compounds have been conducted in rabbits. As those routes of administration are not reflecting the exposure situation but an artificial model, they were fully evaluated, but not regarded as relevant (listed in appendix 2).

Although several studies with monkeys were performed (Schepers 1991/64, Vorwal 1968, Conradi 1971, Wagner 1969), none can be considered to reliably cover the

---

<table>
<thead>
<tr>
<th></th>
<th>proteinosis (rats only)</th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>NiO</td>
<td>Chronic inflammation (rats and mice).</td>
<td>1.25 0.6 31-65 98-100</td>
</tr>
<tr>
<td>Ni(_3)S(_2)</td>
<td>Chronic active inflammation, fibrosis, and proteinosis</td>
<td>0.6 0.15 12-97 68-100</td>
</tr>
</tbody>
</table>

\(^9\) Both sexes.

\(^{10}\) It should be noted that only 19 animals, divided in 3 dose groups, were exposed under highly variable experimental conditions to beryllium oxide, and that the animal bearing the tumor was from the medium dose group. No tumors were observed in the high dose group.

\(^{11}\) The intention was not to prove carcinogenicity of beryllium, but to demonstrate that the monkey in general was a model for carcinogenicity. Animals were not only exposed to beryllium, but to cigarette smoke and
endpoint carcinogenesis due to either very low animal numbers or low experimental quality/insufficient reporting.

**Oral studies**

Oral exposure to beryllium has not been found to cause cancer in animals. No studies with beryllium metal are available, but even under the worst-case of dietary exposure of dogs, rats and mice to beryllium sulfate (a soluble beryllium compound), no significant increases in the number of lung reticulum cell carcinomas/tumors/neoplasms were observed (Morgareidge et al., 1975, 1976; Schroeder and Mitchener 1975a, 1975b).
3.4.3 Summary of Literature Review: Epidemiological Studies and Data

The epidemiological studies on the association of occupational beryllium exposure and cancer can be divided into different phases and issues due to different size or type of study populations, quality of exposure assessment and other factors that determine the validity and limitations of epidemiological studies.

- Early cohort studies on workers employed at two major beryllium processing plants in the USA;
- Cohort studies using data of the Beryllium Disease Registry;
- More recent studies using improved assessments of confounding, type of employment and exposure.

Table 3 Summary of human epidemiology studies on beryllium*

<table>
<thead>
<tr>
<th>Type of study</th>
<th>Relationship observed</th>
<th>Data Quality [Klimisch 1-4]</th>
<th>Reference</th>
</tr>
</thead>
<tbody>
<tr>
<td>Retrospective cohort mortality study</td>
<td>Authors state that altered risk of cancer can not be evaluated by the study</td>
<td>4 (not corrected for confounding, no detailed statistical analysis)</td>
<td>Mancuso et al, 1969</td>
</tr>
<tr>
<td>Extension of Mancuso et al (1969)</td>
<td>Risk of lung cancer was highest among workers employed 1-2 quarters (3-6 months). There was also a higher risk of lung cancer among workers with prior occupational respiratory illness</td>
<td>4 (not corrected for confounding, no detailed statistical analysis)</td>
<td>Mancuso et al, 1970</td>
</tr>
<tr>
<td>Retrospective cohort mortality study</td>
<td>Excess risk of lung cancer in workers with 15 or more years since onset of beryllium exposure</td>
<td>4 (study population compared to general population, correction for smoking questionable)</td>
<td>Wagoner et al 1980</td>
</tr>
<tr>
<td>Retrospective cohort mortality study</td>
<td>Excess risk of lung cancer in beryllium workers with 15 years of onset since exposure</td>
<td>4 (not corrected for confounding)</td>
<td>Infante et al 1980</td>
</tr>
<tr>
<td>Cohort mortality study (extension of Infante et al (1980))</td>
<td>Excess risk of lung cancer in beryllium workers</td>
<td>4 (smoking data was only available for part of the study population, correction is unclear)</td>
<td>Steenland et al 1991</td>
</tr>
<tr>
<td>Retrospective cohort mortality study</td>
<td>Excess risk of lung cancer identified for beryllium workers</td>
<td>3 (exposed individuals mainly living in cities were compared to rural population)</td>
<td>Ward et al., 1992</td>
</tr>
<tr>
<td>Re-analysis of the study by Ward et al (1992)</td>
<td>No association between occupational exposure to beryllium and lung cancer</td>
<td>2 (comparing the study population to adequate (city) controls)</td>
<td>Levy et al., 2002</td>
</tr>
<tr>
<td>Re-analysis of the</td>
<td>No association between time worked</td>
<td>2 (well-documented re-</td>
<td>Levy et al., 2009</td>
</tr>
<tr>
<td>Study</td>
<td>Methodology and Results</td>
<td>Author(s)</td>
<td></td>
</tr>
<tr>
<td>--------------------------------------</td>
<td>----------------------------------------------------------------------------------------</td>
<td>--------------------------</td>
<td></td>
</tr>
<tr>
<td>Study by Ward et al., 1992</td>
<td>and age at hire with lung cancer analysis using Cox proportional hazards analysis)</td>
<td>Williams, 1996</td>
<td></td>
</tr>
<tr>
<td>Mortality and autopsy study of subjects in the UK beryllium registry</td>
<td>No tumours identified</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Nested case-control study (to Ward et al., 1992)</td>
<td>Excess risk of lung cancer in beryllium workers when 10- or 20-years lag was included</td>
<td>Sanderson et al., 2001b</td>
<td></td>
</tr>
<tr>
<td>Re-analysis of the study by Sanderson et al., (2001b)</td>
<td>No association between occupational exposure to beryllium and lung cancer</td>
<td>Levy et al., 2007</td>
<td></td>
</tr>
<tr>
<td>Re-analysis of the study by Sanderson et al., (2001b)</td>
<td>Increased risk of lung cancer following average exposure (10 year lag) to beryllium, no increased risk following cumulative exposure to beryllium</td>
<td>Schubauer-Berigan, 2010</td>
<td></td>
</tr>
<tr>
<td>Comment on the current knowledge on occupational exposure to beryllium and risk of lung cancer</td>
<td>Beryllium data was not analysed in this study</td>
<td>Deubner et al., 2009</td>
<td></td>
</tr>
</tbody>
</table>

*Studies in light-grey font colour are older work with methodological shortcomings. Bold-print studies are original work. All studies are summarized in Appendix 4.*

The early epidemiological studies were not found reliable (indicated in grey color above) due to shortcomings in exposure reporting and potential confounding factors were not adequately addressed. They were recently reviewed in detail (Hollins et al., 2009).

Repeated cohort mortality studies of US beryllium workers suggested the rate of lung cancer compared to community rates might be modestly increased, e.g. standard mortality ratio 1.26, p > 0.01, but found no other cancer excess (Ward, 1992). The modestly higher lung cancer rate in beryllium workers appears to be fragile. Using the same data as Ward, the standard mortality ratio has been estimated as low as non-significant 1.01, p> 0.05 when variations in the community groups to which workers are compared, methods for smoking rate correction, and different methods for summing results across the beryllium production facilities are considered, (Levy & Roth, 2002).

A subsequent study, based on the same data as Ward et al., 1992, estimated exposure and analyzed exposure-response directly. This study found that beryllium workers with lung cancer did not have higher average, maximum or cumulative exposures to beryllium (Sanderson et al., 2001). When exposure was adjusted for latency, the assumed time from lung cancer induction to death, workers with lung cancer appeared to have had higher beryllium exposure. However, it has been demonstrated that this result is an artifact of the statistical method. When the artifact was corrected, workers who developed lung cancer did not have higher beryllium exposure than other workers.
whether or not exposure was adjusted for latency (Levy et al., 2007). This artifact was verified empirically by a simulation study (Deubner et al., 2007). The two latest studies on beryllium occupational exposure and risk of cancer (Levy et al., 2009 and Schubauer-Berigan et al., 2008) were also based on the original dataset used in Ward et al. 1992. The Schubauer-Berigan study used date of birth and age at hire as covariates and did not find that time worked with beryllium nor cumulative beryllium exposure was associated with lung cancer.

The main observation regarding these studies is that the outcome is largely dependent on the statistical approach, including the use of confounders and latency period. As evidenced by the number of publications discussing the occupational exposure to beryllium and risk of lung cancer over the last 10+ years, there is an ongoing scientific debate regarding the appropriateness and suitability of the different approaches. It should be emphasized that the majority of these studies are nevertheless based on the same dataset originally presented by Ward et al. 1992. Accordingly, the reliability of these studies depends on the quality of this dataset.

It was suggested over two decades ago that there was not a beryllium exposure – lung cancer response relationship in beryllium workers. To paraphrase Sir Richard Doll (Doll, 1985), “If beryllium workers were indeed exposed to lung cancer risk by their work with beryllium, it was not manifest in the trend of lung cancer with duration of employment.” In the US beryllium worker populations studied, most of the lung cancer observed is in workers who stayed in the beryllium workplace less than one year, with no increase in rate in persons who stayed longer (Ward et al., 1992).

IARC (1993) hypothesized an exposure-response relationship by comparing the magnitude of standardized mortality ratios (SMRs) for lung cancer in different worker groups assumed to have greater or lesser exposure to beryllium. This approach to examining exposure response was deemed to be problematic due to: 1) intrinsic lack of comparability of SMRs, which are indirectly standardized, 2) \textit{ad hoc} method of selection of groups to be compared, 3) lack of exposure data on the groups compared, 4) lack of tests of statistical significance of the difference between the SMRs, 5) lack of control of confounding and 6) the interpretation of the consistent results from redundant observations (repeated studies on the same worker populations) as validating the studies.

It is apparent that the issue of the short-term workers being the most susceptible and the fact that Sanderson did not match on employment years has raised questions and skepticism regarding the carcinogenicity of beryllium.
3.4.4 Summary of new studies performed on Beryllium metal

Additional studies have been performed by Harlan Laboratories Ltd. on beryllium metal. These studies were all according to guideline and performed under GLP.

1) Acute oral toxicity (OECD 423, GLP)
Beryllium powder was suspended in polyethylene glycol 300 (PEG 300) and administered to total of 6 female rats. The animals were then observed for the next 14 days for viability, clinical signs, and bodyweight development. At the conclusion of the study, the animals were also subjected to a macroscopic necropsy. No mortality or clinical signs indicative of toxicity of toxicity were observed. Bodyweight development was also normal. The only observation noted was feces stained grey on first day of observation. This was due to staining by beryllium powder. It is concluded that the LD$_{50}$ following oral administration of beryllium powder was above 2000 mg/kg bw. Accordingly, no classification for acute oral toxicity is considered required for beryllium metal.

2) Skin irritation (OECD 404, GLP)
Beryllium powder (0.5 g) was moistened with water (0.5 ml) and applied to the skin of three New Zealand white rabbits for 4 hours. The test item was then removed by flushing with lukewarm water. The skin reaction was assessed 1, 24, 48, and 72 hours after exposure. There were no indications of skin irritation at any of the timepoints. Accordingly, no classification for skin irritation is considered required for beryllium metal.

3) Eye irritation (OECD 405, GLP)
Beryllium powder (0.1 g) was instilled into the conjunctival sac of the left eye of three New Zealand white rabbits. The right eye was left untreated and served as control. The eye reaction was evaluated after 1, 24, 48, and 72 hours, and 7 days after exposure. There were no reactions in the cornea or iris. There was however a mild and transient redness of the conjunctiva (mean 24-72 hour value of 1 on the Draize scale). This redness was completely gone after 7 days. No classification for eye irritation is considered required as the reactions seen did not fulfill the criteria of EU Directive 2001/59/EC and EU Regulation 1272/2008.

4) Skin sensitization (OECD 406, GLP)
Beryllium powder was suspended in PEG 300 to a 15% concentration and injected intradermally together with Freund’s adjuvant in the dorsal skin of the scapular region. One week later the same area was clipped free of hair and a 50% solution (0.3 ml) of beryllium powder in PEG 300 was applied. The test item was held in contact with the skin for 48 hours. Control animals were treated the same way but with vehicle only. The animals were challenged two weeks by applying 0.2 ml of a 10% solution of beryllium powder to the left flank while the vehicle only was applied to the right flank. The test substance was held in contact with the skin for the next 24 hours. The skin reaction was then assessed 24 and 48 hours after removal of the substance. No skin reactions were observed in the control group or in the treated group. Accordingly, no classification for skin sensitization is considered required for beryllium metal.

5) Bacterial reverse mutation test (OECD 471, GLP)
Beryllium metal was extracted by shaking with physiological saline for 3 days at 37°C. The following concentrations were achieved in two separate experiments: 733.7 µg/ml
and 124.0 µg/ml. Dilutions of 2.5, 5, 10, 20, 40, 60, 80 and 100% of the beryllium solutions were used in the main experiment. The main experiment was performed in the following strains: TA 1535, TA 1537, TA 98, and TA 100. In the plate incorporation assay the bacterial strains were incubated with the test item extract, metabolic activation system (rat liver S9 mix) or not, and overlay agar. The mixture was poured on selective agar plates, allowed to solidify and incubated for at least 48 h in the dark. The preincubation assay was performed in a similar manner however with a 60 minute preincubation period before plating. The performance of the system was verified by using known mutagens (with and without metabolic activation). No cytotoxicity was observed at any of the concentrations tested. There was no increase in revertant colonies following exposure to beryllium metal extracts with and without metabolic activation.

6) Mammalian chromosome aberration (OECD 473, GLP)
As beryllium metal is relatively insoluble, it was extracted at 37°C for 3 days at a loading rate of 100 mg/l in the cell culture medium used in the assay under non-abrasive shaking. Extract concentration of 3.258/20.27 µg Be/ml culture medium with FCS and 20.83/4.434 µg Be/ml culture medium without FCS were analytically found in the extracts prepared for the first/second experiment. The extracts were used to expose the cells at 100% (pure extract), 75% and 50%. Human whole blood cultures were set up. After 72 h, the cells were incubated with the test item extracts for 4 or 22 hours in presence or absence of a metabolic activation system (rat liver S9 mix), respectively (cell culture medium of cultures with 4 hours exposure was replaced by fresh test item-free culture medium after that period). 19 hours after start of exposure, colcemid was added to the cultures to arrest cells in metaphase. Three hours later, cells were washed, fixed, metaphases stained and microscopically evaluated. All experimental conditions were tested in two independent cell cultures. The experiment was repeated for confirmation. Statistically significant increase in the number of structural chromosome aberrations was observed only at one incidence (22 h of 75% extract). As this increase was not dose-dependent (no increase at 100% extract), within the historical control data of the laboratory and was not reproducible in the repeat experiment, it was considered incidental. Beryllium metal powder, extracted at worst-case conditions in culture medium for cell exposure, was not clastogenic in human lymphocytes.

7) Mammalian mutation (OECD 476, GLP)
Due to insolubility of the test item in cell culture media, the test item was extracted at 37°C for 3 days at a loading rate of 100 mg/l in the culture medium used in the assay under non-abrasive shaking. The extracts were used to expose the cells. The following concentrations were achieved: 3.12 µg Be/ml culture medium were analytically found in the extract prepared for the first experiment; 4.477 µg Be/ml culture medium without FCS were analytically found in the extract prepared for the second experiment; 14.02 µg Be/ml in the extract prepared with FCS. The assay was performed in two independent experiments. V79 cells were exposed to the test item extracts for 4 h with and without metabolic activation (rat liver S9 mix), or for 24 h in absence of metabolic activation. The highest concentration of the test item extract was 100%, and the lowest concentration investigated was 12.5%. Three days after treatment, cells were subcultivated. After an expression time of 7 days, cells were again subcultivated and 6-thioguanine was added to the culture medium to kill all cells that were not mutated in the HPRT-locus. Surviving cells were allowed to form colonies within 8 days. Colonies were stained, their size evaluated, and counted. Cell survival was determined after treatment (parallel cultures) and after subcultivation. The performance of the test system was
proven by parallel experiments with known mutagens. Beryllium metal powder extracts did not induce mutations in the HPRT locus of V79 cells.

8) Unscheduled DNA synthesis
Due to insolubility of the test item in cell culture media, the test item was extracted at 37°C for 3 days at a loading rate of 100 mg/l in the culture medium used in the assay under non-abrasive shaking. The extracts were used to expose the cells.
The UDS study contains the results from many different experiments. Freshly isolated rat hepatocytes were exposed to 0, 50% or 100% of beryllium metal extract with 0, 0.67, 1.19, 1.71, or 2.23 µg/ml 2-AAF for 18 hours in the presence of 3HTdR (methyl-3H-thymidine). The uptake of radioactivity was determined by autoradiography. Vehicle control groups and cultures treated only with the beryllium metal powder extract were tested in parallel. For each concentration, including the controls, 100 cells were evaluated. In the DNA repair assay the mutagen (2-AAF) alone was always able to induce relevant DNA repair synthesis (distinct increase in the number of nuclear and net grain counts as well as % cells in repair). No increase in DNA repair was observed for cells treated with the test item extract alone. When cells were treated in parallel with the mutagen 2-AAF a distinct decrease of the of the mean net grain counts and of the amount of cells in repair was found after treatment with 100 % of the test item extract. However, a clear dose dependence was not observed. It is concluded that beryllium metal extract did not cause DNA damage in this study but at the highest dose exerted an effect on the repair of pre-existing DNA damage.

9) Cell transformation assay (OECD Draft Proposal: In vitro Syrian hamster embryo (SHE) cell transformation assay, GLP)
As beryllium is relatively insoluble in cell culture media, the test item was extracted at 37°C for 3 days at a loading rate of 100 mg/l in the culture medium used in the assay under non-abrasive shaking. The extracts were used to expose the cells. A concentration of 22.95 µg Be/ml culture medium was analytically found in the extract prepared for the experiment. Female and male hamsters were mated, and the pregnant females sacrificed in day 13 of gestation. Embryos were isolated from the uteri, decapitated, eviscerated and delimbed and the remaining parts minced in washing solution. Cells were obtained by stirring the pieces in trypsin/pancreatin solution for 10 min., and recovery of the isolated cells from the supernatant by centrifugation. Cells were plated, dead cells removed after 3-4 hours by washing, and cells were allowed to expand for 20 hours. Thereafter, cells were trypsinized and stored frozen in liquid nitrogen until use. For the experiments, a first layer of cells was seeded on culture dishes and lethally irradiated (feeder cells). The next day, the target cells were seeded on top of the feeder cells. The cells were incubated with the test item extracts (25-100%) for 7 days continuously to allow colony formation. Thereafter, cells were fixed with methanol, stained with Giemsa and microscopically evaluated for colony morphology. No metabolic activation system was used, as the primary SHE cells have enough metabolic capacity. Performance of the test system was proven by parallel experiments with benzo[a]pyrene. No cytotoxicity was observed at any of the concentrations tested. Beryllium metal powder extracts induced a criss-cross growth of cells within the colonies, which is different compared to the normal waive-like growth of SHE cell colonies.
Summary of new studies performed with beryllium metal

Although study 1-4 is not relevant for the assessment of carcinogenic potential they have been included in this summary for the purpose of completeness. They clearly demonstrate that beryllium metal is not acutely toxic and does not cause eye and skin irritation, or skin sensitization. The remaining studies also clearly demonstrate that beryllium metal does not induce DNA damage (mutagenic or larger structural rearrangements). Extract of beryllium metal did also not induce unscheduled DNA synthesis, indicative of DNA damage, in the UDS study. The same experiment also investigated the effects of co-incubating with beryllium and the positive control, 2-acetylaminofluorene. It was observed that beryllium had an effect on DNA repair synthesis (suppressed) at the highest concentration of 2-aminofluorene (96% of cells in repair synthesis). The cell transformation assay indicated that beryllium metal extracts can induce changes in colony morphology of Syrian hamster embryo cells. However, the mechanism behind this effect, and the relevance to human exposure, can not be determined. As the genotoxicity tests were all negative, it is excluded that the morphological change observed is due to mutation or chromosome structural changes.

4 SUMMARY AND CONCLUSIONS

According to Annex VI of Directive 67/548/EEC, No. 4.2.1, the comments regarding the categorisation of carcinogenic substances read as follows:

“The placing of a substance into category 1 is done on the basis of epidemiological data; placing into categories 2 and 3 is based primarily on animal experiments. For classification as a category 2 carcinogen either positive results in two animal species should be available or clear positive evidence in one species, together with supporting evidence such as genotoxicity data, metabolic or biochemical studies, induction of benign tumours, structural relationship with other known carcinogens, or data from epidemiological studies suggesting an association.”

For a distinction between categories 2 and 3 the arguments listed below are relevant which reduce the significance of experimental tumour induction in view of possible human exposure. These arguments, especially in combination, would lead in most cases to classification in category 3, even though tumours have been induced in animals: carcinogenic effects only at very high dose levels exceeding the maximal tolerated dose. The maximal tolerated dose is characterised by toxic effects which, although not yet reducing lifespan, go along with physical changes such as about 10 % retardation in weight gain, appearance of tumours, especially at high dose levels, only in particular organs of certain species known to be susceptible to a high spontaneous tumour formation, appearance of tumours, only at the site of application, in very sensitive test systems (e.g. i.p. or s.c. application of certain locally active compounds), if the particular target is not relevant to man, lack of genotoxicity in short-term tests in-vivo and in-vitro, existence of a secondary mechanism of action with the implication of a practical threshold above a certain dose level (e.g., hormonal effects on target organs or on mechanisms of physiological regulation, chronic stimulation of cell proliferation), existence of a species-specific mechanism of tumour formation (e.g. by specific metabolic pathways) irrelevant for man. For a distinction between category 3 and no classification arguments are relevant which exclude a concern for man: a
substance should not be classified in any of the categories if the mechanism of experimental tumour formation is clearly identified, with good evidence that this process cannot be extrapolated to man, if the only available tumour data are liver tumours in certain sensitive strains of mice, without any other supplementary evidence, the substance may not be classified in any of the categories, particular attention should be paid to cases where the only available tumour data are the occurrence of neoplasms at sites and in strains where they are well known to occur spontaneously with a high incidence."

According to Regulation 1272/2008/EEC, the comments regarding the categorisation of carcinogenic substances read as follows:

**Category 1: Known or presumed human carcinogens**

A substance is classified in Category 1 for carcinogenicity on the basis of epidemiological and/or animal data. A substance may be further distinguished as:
- Category 1A: Category 1A, known to have carcinogenic potential for humans, classification is largely based on human evidence, or
- Category 1B: Category 1B, presumed to have carcinogenic potential for humans, classification is largely based on animal evidence.

The classification in Category 1A and 1B is based on strength of evidence together with additional considerations (see section 3.6.2.2). Such evidence may be derived from:

- human studies that establish a causal relationship between human exposure to a substance and the development of cancer (known human carcinogen); or

- animal experiments for which there is sufficient (1) evidence to demonstrate animal carcinogenicity (presumed human carcinogen). In addition, on a case-by-case basis, scientific judgement may warrant a decision of presumed human carcinogenicity derived from studies showing limited evidence of carcinogenicity in humans together with limited evidence of carcinogenicity in experimental animals.

**Category 2: Suspected human carcinogens**

The placing of a substance in Category 2 is done on the basis of evidence obtained from human and/or animal studies, but which is not sufficiently convincing to place the substance in Category 1A or 1B, based on strength of evidence together with additional considerations (see section 3.6.2.2). Such evidence may be derived either from limited (1) evidence of carcinogenicity in human studies or from limited evidence of carcinogenicity in animal studies.

As presented previously, most of the animal studies are not reliable in terms of modern study design. Carcinogenicity has been observed in rats and the reliable studies on beryllium metal and beryllium-containing alloys in mice suggest that only the sensitive strains developed tumours.

The most recent epidemiological studies in man suggest that beryllium is not carcinogenic to man. These studies suggest that the issue of study design is so complex that its behavior is generally not correctly predicted a priori by highly qualified persons and such issues are generally only grasped by experts in the field of study design and analysis of methodological flaws.
Nevertheless, using the criteria in Annex VI of Directive 67/548/EEC would suggest that a reclassification of beryllium metal from a Category 2 to Category 3 may be appropriate based on the missing clear carcinogenicity response in a second animal species (only rat and sensitive mouse strains, no clear carcinogenicity in wild-type mice, guinea pigs and monkeys) and the convincing new evidence relative to human epidemiology. The same arguments can be made for classification according to Regulation 1272/2008 and an H351 (Category 2) classification is proposed.

Aspects of the epidemiology studies which limit their relevance:

- The relatively low excess risk for lung cancer in most of the worker populations;
- The deficiencies with regard to measurements of exposures to beryllium, in particular in the 1940s and 1950 years;
- Deficiencies to control for the contributions of confounders such as smoking habits and possible other chemical carcinogens that workers may be exposed to in work places of the beryllium industry;
- Intrinsic lack of comparability of SMRs, which are indirectly standardized;
- Ad hoc method of selection of groups to be compared;
- Lack of tests of statistical significance of the difference between the SMRs;
- The interpretation of the consistent results from redundant observations (repeated studies on the same worker populations) as validating studies;
- Failure to account for short term worker effect.

Some additional remarks regarding beryllium-containing alloys:

The experimental basis for beryllium-containing alloys appears to be scarce with regard to mutagenicity and carcinogenicity and needs consideration. Beryllium alloys typically contain less than 2% beryllium but every alloy is unique, with physical, mechanical and chemical properties that differ significantly from the components from which it is formed. Once formed, an alloy cannot be easily separated into its components by physical means. Consideration should be given to alloy metallurgy and the science associated with alloys with regard to any cancer designation for beryllium-containing alloys as well as other alloys.

Itingen, 28/10/2010

Christian Strupp, Dr. rer. Nat

Bjarte Furnes, PhD
APPENDIX 1

Databases Screened

PubMed

MedPilot:
  AMED
  AnimAlt-ZEBET
  BIOME
  BIOSIS PREVIEWS
  CAB ABSTRACTS
  CancerLit
  CCMed
  CCRIS (Toxikologie)
  Cochrane (DARE)
  Cochrane-Reviews (CDSR)
  Deutsches Ärzteblatt
  DIQ-Literatur
  EMBASE
  EMBASE Alert
  ETHMED
  EZB Regensburg
  GeroLit
  GLOBAL Health
  IPA International Pharmaceutical...
  ISTPB + ISTOP/ISSHP
  Karger-Verlagsdatenbank
  Katalog: Deutsche Zahnärztedbibli...
  Katalog: NLM
  Katalog: ZB MED Ernährung/Umwelt
  Katalog: ZB MED Medizin
  Kluwer-Verlagsdatenbank
  Krause & Pachernegg Publikations...
  Lehmanns Online Bookshop
  Link-Datenbank der ZB MED
  Link-Datenbank der ZB MED
  Lippincott Williams & Wilkins Ve...
  Medline
  Medline Alert
  OldMedline
  Pressedienste Gesundheitswesen
  PsycINFO
  Psyndex
  SCISEARCH
  SOCIAL SCISEARCH
  Springer-Verlagsdatenbank
  Thieme-Verlagsdatenbank
  VVFM Virtuelle Videothek für die...
  Xtoxline

ToxNET:
  HSDB
  IRIS
  ITER
GENE-TOX
CCRIS
Multi-Databases
TOXLINE
DART/ETIC
TRI
ChemIDPlus

**TOXLINE Special**
Special journal and other research literature:
- Developmental and Reproductive Toxicology (DART®)
- International Labour Office (CIS)
- Swedish National Chemicals Inspectorate (RISKLINE)

Technical reports and research projects:
- Federal Research in Progress (FEDRIP)
- Toxic Substances Control Act Test Submissions (TSCATS)
- Toxicology Document and Data Depository (NTIS)
- Toxicology Research Projects (CRISP)

Archival collection (no longer being updated):
- Aneuploidy (ANEUPL)
- Environmental Mutagen Information Center File (EMIC)
- Environmental Teratology Information Center File (ETIC)
- Epidemiology Information System (EPIDEM)
- Hazardous Materials Technical Center (HMTC)
- Health Aspects of Pesticides Abstract Bulletin (HAPAB)
- International Pharmaceutical Abstracts (IPA)
- NIOSHTIC (NIOSH)
- Pesticides Abstracts (PESTAB)
- Poisonous Plants Bibliography (PPBIB)
- Toxicological Aspects of Environmental Health (BIOSIS)